Side by side
Compare toxic profiles
Drop in two or three agents to see how their kidney toxicity diverges — the signature lesion, how often it strikes, how severe and how reversible, and where along the nephron it lands. Useful for choosing between same-class agents.
CisplatinCarboplatinOxaliplatin
| CisplatinPlatinol | CarboplatinParaplatin | OxaliplatinEloxatin | |
|---|---|---|---|
| Class | Platinum agent | Platinum agent | Platinum agent |
| Signature injury | Acute Tubular Necrosis | Acute Tubular Necrosis | Acute Tubular Necrosis |
| Severity | Severe | Mild | Mild |
| Reversibility | Partially reversible | Reversible | Reversible |
| Incidence | 30% | 5% | 2% |
| Onset | Acute — creatinine peaks ~day 4–7; magnesium wasting can persist for months. | Acute when it occurs (high-dose regimens). | Acute if immune-mediated (often on re-challenge). |
| Injury signatures | ATNLYTEPRE | ATNLYTE | ATNTMA |
| Nephron sites | Proximal Tubule · Distal Tubule / Collecting Duct · Vasculature / Endothelium | Proximal Tubule | Proximal Tubule · Vasculature / Endothelium |
| Evidence | 6 refs | 5 refs | 4 refs |
| Full profile | Full profile | Full profile |